J Korean Soc Spine Surg.  2016 Jun;23(2):84-92. 10.4184/jkss.2016.23.2.84.

Comparison of the Efficacy and Safety Profiles of a Pelubi Sustained Release Tab Versus a Pelubi Tab in Patients with Chronic Back Pain: A Randomized, Double-Blind, Multi-Institution Phase III Study

• Kim KT
• Kim TK
• Choi JW
• Ahn JS
• Koh YD
• Kim YW
• Lee JH

• KMID: 2328001
• DOI: http://doi.org/10.4184/jkss.2016.23.2.84

Abstract

STUDY DESIGN: A randomized, double-blind, multi-institution, phase III study.
OBJECTIVES
To evaluate the efficacy and safety of the Pelubi Sustained Release (SR) Tab in patients with chronic back pain, in comparison with the Pelubi Tab, whose efficacy has already been approved, a phase 3 clinical trial was conducted. SUMMARY OF LITERATURE REVIEW: The Pelubi Tab Has shown clinical efficacy in patients with back pain.
MATERIALS AND METHODS
From April 11, 2014 to July 24, 2014, 166 chronic back pain patients were recruited as subjects through a multi-institution, double-blind, random sample. We compared the experimental and control groups' clinical efficacy, which was estimated by the 100-mm Pain Visual Analog Scale (VAS) after 28 days of medication. We also compared the treatment efficacy of both drugs by using a variation of the Oswestry Disability Index (ODI) and Physician Global Assessment (PGA), with the total usage of relief medicine. The side effects and clinical pathology were also noted.
RESULTS
Neither group showed a significant difference in 100-mm Pain VAS or ODI variation (p=0.1702, p=0.9041). There was no statistically significant difference between the experimental group and the control group in PGA or total usage of relief medicine. The ODI and PGA variation were not worse in the experimental group than the control group. The two groups showed no significant differences in side effects (p=0.9708).
CONCLUSIONS
This study found that the Pelubi SR Tab applied to back pain patients was not inferior to the Pelubi Tab and did not show any significant difference in terms of safety. The Pelubi SR Tab can be used with the same expectation of safety as the Pelubi Tab.

Keyword

Pelubi SR Tab; Random sampling; Double blind

MeSH Terms

Back Pain*
Humans
Pathology, Clinical
Treatment Outcome
Visual Analog Scale

Reference

1. Shin BJ, Kim TK, Baik JS, et al. Comparison The Safety and The Efficacy between the Group of using Pelubiprofen Tab. and the Group of using Aceclofenac Tab. on Back Pain Patients - Multi Institution, Double Blind, Random Sample. J Korean Soc Spine Surg. 2012; 19:38–46.

2. Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999; 354:581–5.

3. Hart LG, Deyo RA, Cherkin DC. Physician office visits for low back pain frequency, clinical evaluation, and treatment patterns from a U.S. national survey. Spine (Phila Pa 1976). 1995; 20:11–9.

4. Burton AK, Waddell G. Clinical guidelines in the management of low back pain. Baillieres Clin Rheumatol. 1998; 12:17–35.

5. Desmeules J, Rollanson V, Piguet V, et al. Clinical pharma-cology and rationale of analgesic combination. Eur J An-aesthesiol Suppl. 2003; 28:7–11.

6. Kuritzky L, Samraj GP. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J Pain Res. 2012; 5:579–90.

7. Cherkin DC, Wheeler KJ, Barlow W, et al. Medication use for low backpain in primary care. Spine (Phila Pa 1976). 1998; 23:607–14.

8. Bernstein E, Carey TS, Garrett JM, et al. The use of muscle relaxant medications inacute low back pain. Spine (Phila Pa 1976). 2004; 29:1346–51.

9. Luo X, Pietrobon R, Curtis LH, et al. Prescription of non-steroidal anti-inflammatorydrugs and muscle relaxants for back pain in the United States. Spine (Phila Pa 1976). 2004; 29:E531–7.

10. Luo X, Pietrobon R, Hey L. Patterns and trends in opioid use among individualswith back pain in the United States. Spine (Phila Pa 1976). 2004; 29:884–90.

11. Di Iorio D, Henley E, Doughty A. A survey of primary care physician practicepatterns and adherence to acute low back problem guidelines. Arch Fam Med. 2000; 9:1015–21.

12. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclo-oxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004; 23:9247–58.

13. Chung JW, Zeng Y. Drug therapy for the treatment of chronic nonspecific low back pain: systematic review and meta-analysis. Pain physician. 2013; 16:E685–704.

14. Lee YW. Analgesics for Lower Back Pain. J Korean Med Assoc. 2006; 49:665–73.